All In Biotech

Drug Trial Radar · NCT06360354

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Actual

Start

May 29, 2024

Primary completion

Oct 31, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.

Conditions

  • Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Interventions

  • AnvumetostatDrug

    Administered Orally

  • GemcitabineDrug

    Administered IV

  • Nab-paclitaxelDrug

    Administered IV

  • Modified FOLFIRINOXDrug

    Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV

  • RMC-6236Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose Limiting Toxicities (DLT)Time frame: Up to 28 days
  2. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)Time frame: Up to approximately 2 years
  3. Number of Participants Experiencing Serious Adverse Events (SAE)Time frame: Up to approximately 2 years

Locations

77 sites in 16 countries. Site status is shown where the registry gives one.

  • Comprehensive Blood and Cancer Center

    Bakersfield, California

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope Orange County Lennar Foundation Cancer Center

    Duarte, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • Translational Research in Oncology US Inc, Trio Central Pharmacy

    Los Angeles, California

  • University of California Los Angeles

    Santa Monica, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Norwalk Hospital

    Norwalk, Connecticut

  • University of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University

    Durham, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • United States Oncology Regulatory Affairs Corporate Office

    Nashville, Tennessee

  • Oncology Consultants Cancer Center

    Houston, Texas

  • US Oncology Research Investigational Products Center

    Irving, Texas

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • Virginia Cancer Specialists PC

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • Northwest Cancer Specialists - Vancouver

    Vancouver, Washington

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia

  • GenesisCare -North Shore Oncology

    St Leonards, New South Wales, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Austin Health, Austin Hospital

    Heidelberg, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Epworth Healthcare

    St Albans, Victoria, Australia

  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.